Merck, a maker of Ivermectin (IVM), is getting much positive press coverage for its forthcoming prescription oral antiviral (molnupiravir). It is designed to replace IVM that they cannot make big money from. FDA will soon give it emergency use authorization because of the emerging clarity that COVID vaccines do NOT work effectively or safely.
That the Washington Post says that what Merck has created is the “first covid-fighting pill” illustrates how awful big media has been in ignoring the proven benefits of the IVM and HCQ generics while ignoring the many failures of COVID vaccines. In its October 2 front-page story on the new Merck pill, it did not even mention IVM or present any data showing IVM as proven even more effective than the new expensive drug tested on only hundreds of people. In contrast, IVM has been used successfully on hundreds of thousands of people to treat and prevent COVID.